Summary & Overview
HCPCS Level II C9066: Injection, sacituzumab govitecan-hziy, 2.5 mg
HCPCS Level II code C9066 denotes the injectable oncology drug sacituzumab govitecan-hziy in 2.5 mg units, used for systemic cancer treatment administered via infusion. This code matters nationally as novel antibody-drug conjugates have significant clinical and cost implications across outpatient infusion settings and hospital outpatient departments. Accurate coding affects claims processing, utilization tracking, and payer coverage determinations for high-cost oncology therapies.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of what C9066 represents, typical sites of service, and the clinical context for use. The publication outlines benchmarks for billing and utilization where available, summarizes relevant policy updates affecting coverage and reimbursement for high-cost oncology injectables, and highlights documentation and billing considerations specific to HCPCS Level II drug units.
This summary is intended for national audiences including billing professionals, oncology practice administrators, and policy analysts seeking a clear overview of the code, payer landscape, and the operational implications of administering and billing sacituzumab govitecan-hziy in outpatient infusion settings.
Billing Code Overview
HCPCS Level II code C9066 represents Injection, sacituzumab govitecan-hziy, 2.5 mg. The service is an injectable oncologic drug administration intended for systemic cancer therapy. The typical site of service for this drug is outpatient infusion centers or hospital outpatient departments, where parenteral oncology therapies are administered. Service line: Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old female with metastatic triple-negative breast cancer, refractory to at least two prior systemic therapies, presents to the outpatient oncology infusion center for administration of sacituzumab govitecan-hziy. The facility verifies orders for C9066 (injection, sacituzumab govitecan-hziy, 2.5 mg), reviews recent laboratory results including complete blood count and liver function tests, confirms intravenous access, and reassesses performance status and concomitant medications. The oncology nurse prepares the dose per pharmacy compounding protocols, initiates premedication per institutional antiemetic and hypersensitivity prophylaxis guidelines, and monitors the patient during infusion for infusion-related reactions, neutropenia, diarrhea, and other adverse events. Post-infusion, the patient is observed for an appropriate period, provided with written and oral discharge instructions, and a follow-up oncology visit is scheduled to assess response and toxicity management. Billing uses C9066 per 2.5 mg unit administered, with applicable modifiers appended as indicated by clinical circumstances.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work required to compound, prepare, or manage complex administration substantially exceeds typical requirements. |